Results 21 to 30 of about 188,005 (273)

alpha-Melanocyte stimulating hormone: production and degradation [PDF]

Journal of Molecular Medicine, 2010
Proopiomelanocortin (POMC) is a polypeptide hormone precursor that is expressed in the brain and in peripheral tissues such as in the pituitary gland, immune system, and skin. In the brain, POMC is processed to form several peptides including alpha-melanocyte stimulating hormone (α-MSH). alpha-MSH is expressed in the hypothalamic arcuate nucleus and in
D'Agostino, Giuseppe, Diano, Sabrina
openaire   +6 more sources

α‐Melanocyte‐stimulating hormone inhibition of oxytocin neurons switches to excitation in late pregnancy and lactation [PDF]

Physiological Reports, 2022
Oxytocin is secreted into the periphery by magnocellular neurons of the hypothalamic supraoptic and paraventricular nuclei (SON and PVN) to trigger uterine contraction during birth and milk ejection during suckling.
Michael R. Perkinson, Matthew K. Kirchner, Meng Zhang, Rachael A. Augustine, Javier E. Stern, Colin H. Brown   +5 more
doaj   +2 more sources

Natriuretic Properties of Melanocyte-Stimulating Hormones

Journal of Cardiovascular Pharmacology, 1993
Proopiomelanocortin (POMC) is a protein that contains the amino acid sequences of numerous peptide hormones, including the melanocyte-stimulating hormones (MSH). MSH peptides of alpha, beta, and gamma primary structure are present in plasma, and all exhibit natriuretic activity.
Jean‐Pierre Valentin, Eckehart Wiedemann, Michael H. Humphreys   +2 more
openalex   +3 more sources

Anti-inflammatory α-Melanocyte-Stimulating Hormone Protects Retina After Ischemia/Reperfusion Injury in Type I Diabetes [PDF]

Frontiers in Neuroscience, 2022
Retinal ischemia/reperfusion (I/R) injury is a major cause of vision loss in many ocular diseases. Retinal I/R injury is common in diabetic retinopathy, which as a result of hyperglycemia damages the retina and can cause blindness if left untreated ...
Rajesh Kumar Goit, Andrew W. Taylor, Amy C. Y. Lo   +2 more
doaj   +2 more sources

Anti-inflammatory treatment using alpha melanocyte stimulating hormone (α-MSH) does not alter osteoblasts differentiation and fracture healing [PDF]

BMC Musculoskeletal Disorders
Background Alpha-melanocyte-stimulating-hormone (α-MSH) has been identified as a new anti-inflammatory treatment compound in rheumatoid arthritis (RA) and other inflammatory diseases.
Johanna Graue, Melanie Timmen, Katharina Schmitz, Daniel Kronenberg, Markus Böhm, Kishor K. Sivaraj, M. Gabriele Bixel, Richard Stange   +7 more
doaj   +2 more sources

The increase of alpha-melanocyte-stimulating hormone in the plasma of chronic fatigue syndrome patients

BMC Neurology, 2010
Background Despite extensive research, no reliable biological marker for chronic fatigue syndrome (CFS) has yet been identified. However, hyperactivation of melanotrophs in the pituitary gland and increased levels of plasma alpha-melanocyte-stimulating ...
Shishioh-Ikejima Nobue, Ogawa Tokiko, Yamaguti Kouzi, Watanabe Yasuyoshi, Kuratsune Hirohiko, Kiyama Hiroshi   +5 more
doaj   +2 more sources

The α‐melanocyte‐stimulating hormone/melanocortin‐1 receptor interaction: A driver of pleiotropic effects beyond pigmentation

Pigment Cell & Melanoma Research, 2021
Melanocortin‐1 Receptor (MC1R), when stimulated by alpha‐melanocyte‐stimulating hormone (α‐MSH), is a driver of eumelanogenesis. Brown/black eumelanin is an effective filter against ultraviolet radiation (UVR) and is a scavenger of free radicals. Several
C. Herraiz, Idoya Martínez-Vicente, V. Maresca   +2 more
semanticscholar   +1 more source

Literature-Based Discovery to Elucidate the Biological Links between Resistant Hypertension and COVID-19

Biology, 2023
Multiple studies have reported new or exacerbated persistent or resistant hypertension in patients previously infected with COVID-19. We used literature-based discovery to identify and prioritize multi-scalar explanatory biology that relates resistant ...
David Kartchner, Kevin McCoy, Janhvi Dubey, Dongyu Zhang, Kevin Zheng, Rushda Umrani, James J. Kim, Cassie S. Mitchell   +7 more
doaj   +1 more source

Rare POMC Mutation in a Patient With Myotonic Dystrophy Type 1 and Adrenocorticotropin Hyperresponse to Corticotropin-Releasing Hormone

AACE Clinical Case Reports, 2019
: Objective: Myotonic dystrophy (DM) is a monogenic disorder. It is caused by expansion of a cytosine-thymineguanine triplet in the DMPK gene which encodes for myotonic dystrophy protein kinase (DMPK).Methods: A 24-year-old man with DM and the DMPK ...
Silvia Cantara, PhD, Francesco Chiofalo, MD, Cristina Ciuoli, MD, Carlotta Marzocchi, MS, Mariaresa Te Dotti, MD, Maccora Carla, MD, MariaGrazia Castagna, MD, PhD, Fabio Giannini, MD   +7 more
doaj   +1 more source

A feasibility and safety study of afamelanotide in acute stroke patients – an open label, proof of concept, phase iia clinical trial

BMC Neurology, 2023
Background Neuroprotective agents have the potential to improve the outcomes of revascularisation therapies in acute ischemic stroke patients (AIS) and in those unable to receive revascularisation.
Vimal Stanislaus, Anthony Kam, Lily Murphy, Philippe Wolgen, Gill Walker, Pilar Bilbao, Geoffrey C Cloud   +6 more
doaj   +1 more source